Fondren Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Fondren Management’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.02M	Sell	137,000 -49,900	-27%	-$443K	6.05%	6
2020 Q2	$1.69M	Sell	186,900 -127,400	-41%	-$1.32M	6.53%	6
2020 Q1	$3.01M	Buy	314,300 +49,400	+19%	+$591K	7.65%	2
2019 Q4	$3.81M	Sell	264,900 -20,248	-7%	-$295K	3.91%	5
2019 Q3	$4.29M	Buy	285,148 +67,836	+31%	+$945K	3.57%	5
2019 Q2	$2.88M	Buy	217,312 +138,312	+175%	+$1.67M	2.74%	11
2019 Q1	$1.04M	Buy	+79,000	New	+$1.15M	0.82%	31

Other funds holding OPNT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fondren Management's OPNT Position: Q3 2020 in Review

Fondren Management reduced its Opiant Pharmaceuticals, Inc. Common Stock (OPNT) stake by 27% in Q3 2020, selling an estimated $443K and leaving 137,000 shares worth $1.02M. The position accounts for 6.05% of the portfolio, ranked #6.

Fondren Management first reported a position in OPNT in Q1 2019 and has held it in 7 quarters since. The position peaked at $4.29M in Q3 2019. 28 funds tracked by Wall St. Rank hold OPNT as of Q3 2020.

Fondren Management held 137,000 shares of Opiant Pharmaceuticals, Inc. Common Stock worth $1.02M as of Q3 2020.
Fondren Management sold 49,900 Opiant Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $443K.
Opiant Pharmaceuticals, Inc. Common Stock made up 6.05% of Fondren Management's portfolio in Q3 2020, its #6 holding.
Fondren Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2019 and has held it in 7 quarters since.
Fondren Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $4.29M in Q3 2019.
28 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Fondren Management's 13F filing for Q3 2020, filed 13 Nov 2020.